Outcomes with various chemoradiotherapy regimens for locally advanced head and neck squamous cell carcinoma

Cetuximab-based and carboplatin-based chemoradiotherapy (CRT) are often used for patients with locally advanced head and neck squamous cell carcinoma (LA HNSCC) who are ineligible for cisplatin. A retrospective cohort study among US Veterans with nonmetastatic LA HNSCC found that one in three patients was ineligible for cisplatin-based chemoradiotherapy. Among these patients carboplatin-based CRT was associated with better overall survival compared with cetuximab-based chemoradiotherapy.